Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 6506  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (659 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  References
 »  Article Tables

 Article Access Statistics
    Viewed1092    
    Printed20    
    Emailed0    
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 7  |  Page : 83-90

Migraine and Vascular Risk: An Update


Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

Date of Submission27-Jan-2021
Date of Decision01-Feb-2021
Date of Acceptance02-Mar-2021
Date of Web Publication14-May-2021

Correspondence Address:
Dr. M V Padma Srivastava
Department of Neurology, Chief Neurosciences Center, All India Institute of Medical Sciences, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.315974

Rights and Permissions

 » Abstract 


Background: Migraine is a common neurological disorder with significant morbidity and disability. There is growing evidence that migraine is associated with cardiovascular diseases and stroke.
Objective: The aim of this study was to provide an update on the association of migraine with some common vascular diseases in persons suffering from the disease and discuss the clinical implications.
Methods and Materials: We searched PUBMED database using the MeSH terms “Stroke”, “Coronary Artery Disease”, “Myocardial Ischemia”, “Atrial Fibrillation”, “White Matter” and “Dementia, Vascular”, in combination with “Migraine Disorders”, “Migraine with Aura” and “Migraine without Aura” and reviewed the relevant studies. We studied articles mostly in English for the past 10 years, without excluding older articles that were relevant to this review. We also searched the reference lists of articles obtained and included some insightful reviews on 'Migraine and Vascular Risk'.
Results: The association between migraine and vascular diseases is strong and consistent for ischemic stroke and migraine with aura especially in young women, with oral contraceptive use and smoking. Although literature reports a higher prevalence of obesity, dyslipidemia, and family history of cardiovascular diseases in migraineurs, the 'migraine-vascular' connection persists in models where the traditional vascular risk factors are adjusted, implicating a migraine-specific pathophysiology at work. There is some evidence linking an adverse vascular risk factor profile to incident myocardial infarction in people with migraine. The association with hemorrhagic stroke is more variable.
Conclusion: Although the absolute effect of migraine on 'vascular risks' is small, good practice parameters dwell on treating and reducing existing cardiovascular risk factors through lifestyle modification, encouraging smoking cessation, and advocating the wise use of agents like ergot alkaloids and oral contraceptives, after a risk-benefit analysis.


Keywords: Aura, migraine, stroke, vascular
Key Messages: Migraine is being increasingly associated with vascular disease. The evidence is robust for migraine with aura and ischemic stroke and variable for other cardiovascular diseases (CVDs). The relationship persists after adjustment of traditional vascular risk factors. The presence of aura, smoking, CVD, age, and estrogen content are important considerations before the use of hormonal agents in women with migraine. Ergot alkaloids/triptans should be avoided in presence of CVD.


How to cite this article:
Gupta A, Srivastava M V. Migraine and Vascular Risk: An Update. Neurol India 2021;69, Suppl S1:83-90

How to cite this URL:
Gupta A, Srivastava M V. Migraine and Vascular Risk: An Update. Neurol India [serial online] 2021 [cited 2021 Jun 17];69, Suppl S1:83-90. Available from: https://www.neurologyindia.com/text.asp?2021/69/7/83/315974




Migraine is a common disabling neurologic illness, and affects approximately 20% of the world's population, with the highest prevalence in women of reproductive age group.[1] As per the “Global Burden of Diseases Study” migraine is amongst the leading causes of disability worldwide in individuals less than 50 years of age.[2] A growing body of evidence in literature identifies migraine as a risk factor for stroke and CVD. The association is strongest between migraine with aura (MA) (a third of migraineurs may have an aura associated with headache) and ischemic stroke.[3] Data about hemorrhagic stroke, myocardial infarction, and cardiovascular mortality is less clear. There is a general agreement in the literature that women with migraine are at a higher risk of vascular disease as compared to men. This may be because migraine is more common in women or maybe due to changes in endogenous and exogenous hormone levels. A comparative lack of data for men is an important confounding factor. In this review article, we give an update on the association between some common vascular diseases in persons suffering from migraine and discuss the clinical implications.

Migraine and stroke

Migraine and ischemic stroke

The association between migraine and ischemic stroke has both explicit and fuzzy aspects. The association is particularly stronger for MA, female gender, young age (<45 years old), and use of oral contraceptives and smoking. Many studies including five meta-analyses of observational studies support this contention.[4–8] In these meta-analyses, the relative risk of ischemic stroke in migraine has been reported between 1.73 (1.31, 2.29) to 2.16 (1.89, 2.48) for overall migraine, 1.56 (1.30, 1.87) to 2.41 (1.81, 3.43) for MA, and 1.02 (0.68, 1.51) to 1.83 (1.06, 3.15) for migraine without aura. In general, the risk of stroke in MA is nearly twice as that in people without migraine. The risk is 10 fold in young women who have MA and are current cigarette smokers and oral contraceptive users.[7] The risk is also higher in people with active migraine[9] and frequent attacks.[10],[11] The 'Stroke Prevention in Young Women Study' found that the stroke risk was higher in women with more than 12 attacks per year.[10] The severity of attacks and the longer duration of disease does not seem to play a significant role. The risk in men[7] and in the elderly is more uncertain, except for elderly who smoke, or elderly with the onset of MA in later life (after 50 years of age).[12–14] The functional outcomes are reported to be good.[15],[16] MA and comorbid cardiovascular risk factors are also associated with increased risk of perioperative ischemic stroke.[17] As far as ischemic stroke subtypes are concerned, the 'Atherosclerosis Risk in Communities study' (involving 1622 migraineurs from a community-based cohort of 12,758 participants) found an association between migraine with visual aura in late middle age and increased risk of cardioembolic stroke.[18]

Migraine and transient ischemic attack (TIA)

MA is linked to an increased risk of TIA, although the association is confounded by a possibility of misdiagnosis as migraine aura and TIA are many a time difficult to differentiate. Particularly challenging are case scenarios wherein the aura is atypical, occurs late in life (when the risk of TIA also increases), occurs in a patient with vascular risk factors, and is not associated with headache.[19] Also, a TIA (or any cerebrovascular event) is known to trigger migraine-like headaches,[20] leading to misinterpretation of stroke as 'complicated migraine' and undermining the use of 'associated headache' in the differentiation. Clinically the most relevant points for the distinction between the two entities include onset, progression, and phenomenology. Sudden onset, lack of march/progression (or if at all it progresses the nadir is reached in seconds to a minute), and negative symptomatology, would favor a TIA over migraine aura. Nevertheless, if the aura is different from the previous attacks, atypical, or involves the basilar artery, it would be prudent to do a tissue imaging and a detailed clinical workup for TIA. Arterial spin labeling is a new technique that can be used to differentiate aura from TIA. The hypoperfusion in migraine aura overlaps with adjacent vascular areas and does not follow the strict distribution of cerebral vascular territories.[21] These perfusion changes are reversible.

Migraine and hemorrhagic stroke

The association between migraine and hemorrhagic stroke remains uncertain. Sacco et al. performed a systematic review and meta-analysis (eight studies comprising of four case-control and four cohort studies, involving 320539 individuals with 1600 hemorrhagic strokes) on the association between migraine and hemorrhagic stroke.[22] They reported an overall pooled effect size of 1.48 (95% CI, 1.16, 1.88) for hemorrhagic stroke in participants with any migraine. However, unlike in ischemic stroke, subgroup analysis did not identify increased predisposition in the sub-groups tested, except for higher effect size in women and younger patients (<45 years). Few studies have shown a trend towards an association between hemorrhagic stroke and MA but the conclusions are not firm. Migraine is also associated with hemorrhagic stroke during pregnancy. As per a large population-based study on inpatients in the United States, migraine in the peripartum period was associated with hemorrhagic stroke with an odds ratio of 9.1 (95% CI, 3.0, 27.8).[23] In contrast to the outcome of ischemic stroke in migraine, hemorrhagic strokes are associated with poor outcomes.[24]

Mechanisms of migraine and stroke

Several plausible hypotheses have been contemplated linking stroke with migraine [Table 1][3],[25] and are discussed briefly.
Table 1: Postulated pathophysiological mechanisms of stroke associated with migraine

Click here to view


Cortical spreading depression: Cortical spreading depression is a spontaneous wave of depolarization that spreads across the cortex at a rate of 3–5 mm/min. The depolarization is associated with increased glucose expenditure and activation of metalloproteinases, thus increasing the blood-brain barrier permeability and local hyperemia. This hyperemia is followed by vascular unresponsiveness and prolonged oligemia. It is proposed as a basis of migraine aura and also predisposes the vulnerable brain tissue to ischemic insult.

Endothelial dysfunction: Endothelial dysfunction is thought to affect cerebrovascular reactivity, although studies in this area in migraine depict conflicting results. Migraine particularly with aura is thought to be associated with an inflammatory milieu. Cytokines released during migraine aura contribute to the prothrombotic state. People with migraine and MA harbor biomarkers of inflammation and endothelial injury like C reactive protein, calcitonin gene-related peptide, vascular endothelial growth factor, von Willebrand factor, stable nitric oxide metabolites and, have fewer endothelial progenitor cell levels.[26],[27]

Traditional vascular risk factors: Regarding the role of traditional vascular risk factors, studies have shown an increased association of hypertension, obesity, smoking, and dyslipidemia with migraine, but the results are highly variable.[28–30] Obesity is also thought to affect migraine frequency, severity, duration, and chronification,[31] while smoking increases the risk of stroke in women with MA. Many studies have assessed the burden of traditional risk factors in people with migraine. But the results are extremely variable, probably because of different study designs, selection and sampling criteria, method of capturing the risk factors (questionnaires, medical records, in-person visits), changing definitions, and residual confounding factors.[28] This is particularly true for the association between migraine and hypertension where the data are quite heterogeneous refuting conclusive statements. For migraine and diabetes, there seems to be a negative association, while for factors like obesity, smoking, and family history of CVDs, the literature supports a positive relationship. Migraine also has an association with an unfavorable lipid profile, but the clinical importance of this relationship is not established. Some studies report reduced alcohol consumption in migraine which may be a disadvantage due to the cardioprotective effect of moderate alcohol consumption. There are reports of an increased carotid intima-media thickness in people with migraine, but the association is not conclusive.[32],[33]

How do these traditional risk factors play between the association of migraine and CVDs? Most studies have shown that the connection between migraine and CVDs, particularly stroke, is independent of the usual vascular risk factors.[3] Most of the strokes in migraineurs are not atherothrombotic. In fact, the stroke risk in migraineurs is increased the most in those who have a favorable cardiovascular risk profile except for cigarette smoking which is known to increase stroke risk in these patients. In the WHS, the risk of stroke in MA was proven only in women with the lowest Framingham risk score.[9] These findings suggest that the migraine aura-ischemic stroke connection is probably non-atherosclerotic. On the contrary myocardial infarction (as mentioned above), was seen in the highest Framingham risk score group.[9]

Patent foramen ovale: Patent foramen ovale (PFO) is thought to be mediate cryptogenic stroke and migraine aura through 'paradoxical embolization.' Numerous but not all studies have reported a high prevalence of PFO in people with migraine, especially MA.[34],[35] Studies have also reported a PFO in approximately 65% of patients with migrainous infarction and a lower mean age of stroke in these patients.[36] Although observational studies have reported a beneficial effect of PFO closure on migraine occurrence, the evidence and the risk-benefit ratio are not enough to recommend routine screening and closure of PFO in migraine.[37] PFO should be screened for if there is a cryptogenic stroke in the young or unusual and frequent aura with migraine attacks. Factors like the size of the PFO, right to left shunt at rest, and the presence of an atrial septal aneurysm, should be considered for the decision of closure.[3]

Genetics: Certain genetic disorders like cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), familial hemiplegic migraine (FHM), mitochondrial encephalopathy with lactic acidosis and stroke (MELAS), hereditary endotheliopathy with retinopathy, nephropathy and stroke (HERNS), and cerebroretinal vasculopathy connect migraine and stroke or stroke-like episodes. CADASIL predisposes to stroke through a non-arteriosclerotic, non-amyloid, fibrotic vasculopathy (NOTCH 3 gene mutation on chromosome 19p13 codes for smooth muscle cell receptors on blood vessels). FHM increases susceptibility to a cortical spreading depression. Genome-wide analysis studies also report a shared genetic susceptibility to migraine and stroke.[38],[39] The association is stronger with migraine without aura than MA, and large artery and cardioembolic stroke than small vessel disease.

Oral contraceptive: The use of oral contraceptive pills has been implicated as a risk factor for vascular events in migraine. Estrogens can impact the association between migraine and vascular disease. Endogenous estrogens are known to protect against vascular damage via anti-inflammatory and immunomodulatory activity in women. Exogenous estrogens differ from endogenous estrogens in that they increase C reactive protein in women of reproductive age, increase the production of pro-coagulation factors, reduce the levels of anticoagulant factors, and affect the hepatic synthesis of lipoproteins and triglycerides.[40],[41] Estrogens are also thought to mediate an increase in platelet reactivity and adhesion ability.[42] Studies in the past, including a meta-analysis, have shown a higher risk of ischemic stroke (approximately seven times higher risk) in women with migraine using oral contraceptives.[7] The risk directly correlates with the dose of ethinylestradiol contained in the formulation. 50 micrograms or more of ethinylestradiol has a higher risk of ischemic stroke as compared to low-dose formulations. As per current evidence, low-dose oral contraceptives containing 25 micrograms of ethinylestradiol or less do not increase the vascular risk in women with migraine.[43] A study comparing 20 micrograms EE to three different formulations (30 micrograms EE + drospirenone, vaginal ring, and patch) reported an increased risk of ischemic stroke and myocardial infarction with 30 micrograms oral preparation only, more so in women aged 35 years or older.[44] Few studies have assessed the risk differences of hormonal contraceptive use between migraine with and without aura. In this context, the 'Stroke Prevention in Young Women study' reported an increased risk of ischemic stroke in those who had MA and used hormonal contraceptives along with smoking, but no increase in risk with the use of hormonal contraceptives alone.[10] Another recent study found a six-fold higher risk of stroke in women who had MA and used oral contraceptives, in comparison to women without these risk factors. In women, without aura, the stroke risk was high but unchanged with the use of oral contraceptives.[45] In a systematic review on stroke risk and use of estrogen-containing contraceptives in women with a migraine the odds of stroke ranged from 2.08 to 16.9.[46] The authors recognized that the quality of evidence is low due to small studies and wide confidence intervals. As per existing guidelines, hormonal contraceptives are contraindicated in women with MA.[47–49] WHO also restricts the use to women younger than 35 years of age.[48]

Hormone replacement therapy: The association of vascular risk with hormone replacement therapy (HRT) in patients with migraine lacks clarity due to conflicting data. Both high dose and low-dose formulations have been linked to increased risk in different studies. There are no formal trials comparing different formulations but local HRT,[50] low-dose estrogens, and natural estrogens may be allowed keeping in mind some increased risk of thromboembolism. However, if in a patient on HRT, migraine recurs or worsens HRT should be discontinued. And if the patient develops new-onset headache and aura, a thorough investigation on lines of transient ischemic attack should be done. Also, in postmenopausal women who already have subclinical vascular disease, estrogens are thought to be detrimental to vascular endothelium. If given for a prolonged period in late menopause, even low-dose estrogens associate with a pro-inflammatory state.[29] Thus the age, duration of treatment, and time point of starting HRT in relation to the menopause onset are all important considerations while deciphering the vascular risk with HRT in migraine. Starting HRT late in menopause and prolonged use in an older woman with vascular risk factors would pose a greater risk of vascular disease than a prompt initiation of treatment in the perimenopausal period or young women with atherosclerosis and a relatively shorter administration.

Drugs: Ergot alkaloids and triptans can cause vasoconstriction and increase the risk of ischemic vascular events in a patient with migraine who has comorbid cardio/cerebrovascular disease or uncontrolled vascular risk factors.[3] Prior history of migraine is frequently reported in the reversible vasoconstriction syndrome (RCVS) which is characterized by acute severe headache with or without seizures and transient/persistent focal neurological deficits, multifocal constriction of cerebral arteries, spontaneous resolution within three months). Triptans and ergots are known to precipitate RCVS.[51] Active migraine during pregnancy is another potential predisposing factor for stroke.[23] Women with migraine and stroke risk factors should be considered for high-risk obstetric monitoring.

The absolute risk of stroke with acute migraine therapies (triptans) is estimated to be small (1:100,000).[52] A population-based cohort study (25-80 years of age) from Denmark (2003–2011) reported a borderline higher relative risk for stroke among migraineurs (identified by triptan utilization) in respect to all strokes in the general population (RR 1.07, 95% CI: 1.01–1.14).[16] However, a higher risk of hemorrhagic stroke was observed in women, particularly those aged 25-45 (RR ~ 1.7). As triptan utilization was used as a proxy measure to identify migraine, the risk differences between triptan users and other migraineurs, between migraine with and without aura, are not available from this study. Ergotamine overuse increases the risk of CVD and cerebral ischemia, particularly in patients with established CVD. A retrospective nested case-control study reported an odds ratio of 2.55 (95% CI 1.22, 5.36) for ischemic complications with ergotamine overuse.[53] Overuse of triptans with or without the use of cardiovascular drugs did not increase this risk. The cardiovascular safety of triptans in established CVD is not an issue as per evidence, but as per the label they are contraindicated in patients with stroke, TIA, unstable angina, acute coronary syndrome, and uncontrolled vascular risk factors. Also, as already mentioned triptans and ergotamines can induce vasoconstriction and potentially precipitate RCVS. People with RCVS frequently have a history of migraine. The thunderclap headache of RCVS may be erroneously thought to be a 'bad migraine attack' if the history of time taken for the attack to peak is not properly elicited. Triptans and ergots given in such a setting may aggravate the vasoconstriction. Among the migraine preventives, the recently developed calcitonin gene-related peptide (CGRP) antagonists have been postulated to carry a theoretical risk of impaired compensatory vasodilation during ischemic conditions (CGRP mediate vasodilation). A study compiled data on vascular adverse events from four double-blind, placebo-controlled studies of Erenumab in migraine (chronic or episodic).[54] The incidence was similar across the placebo and Erenumab treatment groups over a period of 12 weeks.

'Migrainous infarction' versus 'migraine with stroke'

From a clinical perspective, ischemic stroke in a patient with migraine can be categorized into one of the following three categories: cerebral infarction of other cause coexisting with migraine, cerebral infarction of other cause presenting with symptoms similar to MA (ischemic cerebral events can trigger migraine-like attacks) or 'migrainous infarction'. Of these, migrainous infarction is defined [by International Classification of Headache Disorders (ICHD)-3] as an attack of MA, where one or more aura symptoms last more than 60 minutes (aura is prolonged, but symptoms are typical of previous attacks for that particular patient), neuroimaging reveals an ischemic brain lesion in the relevant territory and the stroke cannot be attributed to another disorder.[55] It is thus a diagnosis of exclusion. It is uncommon, seen in 0.2%–0.5% of all ischemic strokes[56] and most often involves the posterior circulation. It is postulated that the blood flow during the prolonged aura phase touches ischemic levels.

Migraine, white matter lesions, and cognition

Migraine is also associated with multiple T2 -FLAIR periventricular and deep white matter hyperintensities (4%-59% of migraine population).[57] A meta-analysis of six population-based and 13 clinic-based studies revealed that white matter abnormalities, silent infarct-like lesions and volumetric changes in grey, and white matter regions were more common in participants with migraine than in control groups.[57] The association was strongest for MA (OR 1.68, 95% CI: 1.07, 2.65). The odds of these white matter lesions have been reported to increase with the increasing frequency of migraine (OR 2.6, 95% CI: 1.2, 6.0). Traditional vascular risk factors and migraine-specific drugs do not mediate this association. The clinical significance of these lesions is not clear. A population-based study on 1170 participants (938 – no severe headache, 65 – nonmigraine headache, 167 - migraine out of which 24 had MA), with a mean age of 69 years, did not find a faster decline in cognition over four to five years of follow-up.[58] Longitudinal studies are required to assess the structural progression and the corresponding clinical changes. Systematic reviews on the association between migraine and cognitive decline, in general, have presented heterogeneous results. Studies both support and refute an association between migraine and vascular dementia.[59] There is no role of stroke prophylaxis in patients with white matter hyperintensities or silent infarcts.

Migraine and cardiac disorders

Evidence also suggests that migraine is associated with common cardiovascular risk factors like hypertension, Raynaud's syndrome, ischemic heart disease, and myocardial infarction. As per a large prospective population-based study (Nurse's Health Study II: 115541 women, aged 25–42 years at baseline, free of angina and CVD (CVD) initially, 20 years follow-up) the hazard of myocardial infarction, angina/coronary revascularization, and cardiovascular mortality amounts to a hazard ratio of 1.39, 1.73, and 1.37, respectively.[60] The Women's Health Study (WHS), another large prospective cohort study (27519 women, aged greater than equal to 45 years at study entry, free from CVD at baseline, 11.9 years follow-up) reported increased incident myocardial infarction in patients who had MA and an adverse vascular risk profile (based on Framingham risk score).[9] The Danish nationwide population-based cohort study (51032 patients with migraine, 510320 people from the general population, 19 years follow-up) reported a positive association between migraine and myocardial infarction (adjusted HR 1.49, 95% CI 1.36 to 1.64) and atrial fibrillation/atrial flutter (adjusted HR 1.25, 95% CI 1.16 to 1.36).[61] Autonomic dysfunction may play a role in the pathophysiology of both migraine and AF, and this may predispose older migraineurs to cardioembolic stroke. MA is also associated with an increased risk of venous thromboembolism in younger patients (age <55 years, adjusted HR 3.32, 95% CI, 1.51, 7.31).[62] The association is stronger in people with aura. At present, there is no evidence to say that migraine prevention reduces cardiovascular risk or, to institute primary prevention with antiplatelet or antithrombotics in patients with migraine.[3]

Fallacies behind the association

Despite the recognized associations between vascular disease and migraine discussed above [summarized in [Table 2]], there are caveats that one needs to consider and contemplate upon.
Table 2: Common vascular diseases in people with migraine

Click here to view


The prevalence of the vascular disease is low in young individuals. Indeed, most of the studies investigating the association between migraine and vascular events are retrospective. Few prospective studies are available and some do not differentiate between migraine subtypes. The methodologies used to capture the migraine diagnosis and type (with or without aura) are neither robust nor consistent across different studies. For example, in the Women's Health Study, patients having active migraine were classified into active MA and active migraine without aura by asking if they had an “aura or any indication a migraine is coming”.[9] The possibility that premonitory symptoms are classified as aura by the patient may lead to wrong subtyping. Also, most prospective cohort studies derive the associations using a 'baseline' history of migraine and a 'later' occurrence of stroke/vascular event. Immediate temporal correlation is not available. 'Headache with stroke' may be a manifestation of stroke (for example, hemorrhagic stroke), and stroke may trigger migraine further confounding the associations.

Summary and clinical implications

To summarize, evidence links migraine to an increased risk of CVDs (CVD) and stroke, but the overall absolute risk is small. Are there reliable indicators as to which individuals across the migraineurs are most susceptible? As of now, this information is limited. In general, most of the migraine patients do not have an aura, and migraine without aura has a smaller risk, which is reassuring. MA particularly portends a higher risk of ischemic stroke especially in younger people (<45 years age), female gender, and with the use of oral contraceptives and smoking. Late-onset of migraine aura (after 50 years of age), active migraine, and frequent attacks also increase the risk of ischemic stroke. It is important to differentiate between a migraine aura and TIA (onset, duration, progression, and phenomenology hold the key). If a patient with aura presents with atypical symptoms, symptoms different than his usual aura, symptoms, and signs suggestive of posterior circulation involvement, or increased frequency of aura in later life, magnetic resonance imaging of the brain and detailed vascular workup should be done. ASL perfusion imaging, a contrast-free method may be suitable to assess the reversible perfusion changes during MA and differentiation from TIA. Migrainous infarction should always be considered as a diagnosis of exclusion after a thorough workup for other causes. The association between migraine and hemorrhagic stroke is less clear, younger women (< 45 years age) and the peripartum period is more vulnerable. The association with aura is not clearly established.

The increased risk of stroke in these individuals does not seem to associate with traditional vascular risk factors other than smoking, although a plethora of studies reports an increased prevalence of an adverse vascular risk factor profile in migraine (smoking, hypertension, higher body mass index, dyslipidemia, and family history of CVD). Migraine-specific pathophysiology might play a role. On the contrary, myocardial infarction is more likely to occur in MA and a comorbid bad vascular risk status. It is imperative therefore in daily clinical practice to treat the vascular comorbidities if any and to encourage smoking cessation. At present, there are no recommendations to start drugs like aspirin and anti-thrombotic for the prevention of vascular events in these patients, unless clear nonmigraine indications are present. The role of migraine preventives in reducing future CVD/strokes is not yet established. Drugs like angiotensin-converting enzyme inhibitors and angiotensin receptor-blockers have shown an initial promise as migraine prevention therapies[63] and are known to have a cardiovascular benefit independent of blood pressure reduction. Whether they can modify the cardiovascular risk in migraine, if used as a preventive drug, is yet to be seen.

Ergot alkaloids and triptans can be safely used in recommended dosages in patients who do not have a cardio or cerebrovascular disease or uncontrolled vascular risk factors. Oral hormonal contraceptives should be avoided in women who have MA, are above 35 years of age, smoke, or have an adverse vascular risk profile or pre-existing thrombophilia. Low estrogen-based oral contraceptives may be used in younger women who have migraine without aura. In the peri-menopausal period, hormone replacement therapy if required should be instituted early. Local formulations, low-dose estrogens and natural estrogens have a lower risk of thromboembolism. Long-duration HRT started in the late post-menopause period can be detrimental to vascular health in older women with migraine. The presence of white matter hyperintensities on brain imaging should not prompt starting antiplatelets or anti-thrombotics, in the absence of other indications for these drugs. The clinical relevance of these lesions needs further evaluation in prospective long-duration cohorts.

To conclude, migraine particularly MA is associated with increased risk of stroke and CVD, the strongest association being with ischemic stroke. The specific pathophysiological mechanism is unclear. Aura-associated circulating coagulation markers, systemic endothelial dysfunction, comorbid conditions (like adverse vascular risk factors, PFO, cervical artery dissection, RCVS), exogenous estrogen acting on a diseased endothelium, and acute migraine drugs may play a role. We need to elucidate the specific upstream/downstream pathophysiological pathways that can explain the 'migraine-vascular risk' connection. Future studies should also explore clinical, imaging, and blood biomarkers that can predict an adverse vascular outcome in migraine. Targeted intervention trials on such enriched cohorts may provide useful future strategies to prevent stroke and CVD in people with migraine.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: Updated statistics from government health surveillance studies. Headache 2015;55:21–34.  Back to cited text no. 1
    
2.
Steiner TJ, Stovner LJ, Vos T. GBD 2015: Migraine is the third cause of disability in under 50s. J Headache Pain 2016;17:104.  Back to cited text no. 2
    
3.
Øie LR, Kurth T, Gulati S, Dodick DW. Migraine and risk of stroke. J Neurol Neurosurg Psychiatry 2020;91:593–604.  Back to cited text no. 3
    
4.
Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ 2005;330:63.  Back to cited text no. 4
    
5.
Hu X, Zhou Y, Zhao H, Peng C. Migraine and the risk of stroke: An updated meta-analysis of prospective cohort studies. Neurol Sci 2017;38:33–40.  Back to cited text no. 5
    
6.
Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, et al. Migraine and the risk of cardiovascular and cerebrovascular events: A meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 2018;8:e020498. doi: 10.1136/bmjopen-2017-020498.  Back to cited text no. 6
    
7.
Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ 2009;339:b3914. doi: 10.1136/bmj.b3914.  Back to cited text no. 7
    
8.
Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: An updated meta-analysis. Am J Med 2010;123:612–24.  Back to cited text no. 8
    
9.
Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006;296:283–91.  Back to cited text no. 9
    
10.
MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, et al. Probable migraine with visual aura and risk of ischemic stroke: The stroke prevention in young women study. Stroke 2007;38:2438–45.  Back to cited text no. 10
    
11.
Kurth T, Schürks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology 2009;73:581–8.  Back to cited text no. 11
    
12.
Monteith TS, Gardener H, Rundek T, Elkind MSV, Sacco RL. Migraine and risk of stroke in older adults: Northern Manhattan Study. Neurology 2015;85:715–21.  Back to cited text no. 12
    
13.
Mosek A, Marom R, Korczyn AD, Bornstein N. A history of migraine is not a risk factor to develop an ischemic stroke in the elderly. Headache 2001;41:399–401.  Back to cited text no. 13
    
14.
Androulakis XM, Sen S, Kodumuri N, Zhang T, Grego J, Rosamond W, et al. Migraine age of onset and association with ischemic stroke in late life: 20 years follow-up in aric. Headache 2019;59:556–66.  Back to cited text no. 14
    
15.
Rist PM, Buring JE, Kase CS, Schürks M, Kurth T. Migraine and functional outcome from ischemic cerebral events in women. Circulation 2010;122:2551–7.  Back to cited text no. 15
    
16.
Albieri V, Olsen TS, Andersen KK. Risk of stroke in migraineurs using triptans. Associations with age, sex, stroke severity and subtype. EBioMedicine 2016;6:199–205.  Back to cited text no. 16
    
17.
Timm FP, Houle TT, Grabitz SD, Lihn A-L, Stokholm JB, Eikermann-Haerter K, et al. Migraine and risk of perioperative ischemic stroke and hospital readmission: Hospital based registry study. BMJ 2017;356:i6635. doi: 10.1136/bmj.i6635.  Back to cited text no. 17
    
18.
Androulakis XM, Kodumuri N, Giamberardino LD, Rosamond WD, Gottesman RF, Yim E, et al. Ischemic stroke subtypes and migraine with visual aura in the ARIC study. Neurology 2016;87:2527–32.  Back to cited text no. 18
    
19.
Kurth T, Diener H-C. Migraine and stroke: Perspectives for stroke physicians. Stroke 2012;43:3421–6.  Back to cited text no. 19
    
20.
Waters MJ, Cheong E, Jannes J, Kleinig T. Ischaemic stroke may symptomatically manifest as migraine aura. J Clin Neurosci 2018;55:62–4.  Back to cited text no. 20
    
21.
Wolf ME, Okazaki S, Eisele P, Rossmanith C, Gregori J, Griebe M, et al. Arterial spin labeling cerebral perfusion magnetic resonance imaging in migraine aura: An Observational Study. J Stroke Cerebrovasc Dis 2018;27:1262–6.  Back to cited text no. 21
    
22.
Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and hemorrhagic stroke: A meta-analysis. Stroke 2013;44:3032–8.  Back to cited text no. 22
    
23.
Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ 2009;338:b664. doi: 10.1136/bmj.b664.  Back to cited text no. 23
    
24.
Kurth T, Kase CS, Schürks M, Tzourio C, Buring JE. Migraine and risk of haemorrhagic stroke in women: Prospective cohort study. BMJ 2010;341:c3659. doi: 10.1136/bmj.c3659.  Back to cited text no. 24
    
25.
Gryglas A, Smigiel R. Migraine and stroke: What's the link? What to do? Curr Neurol Neurosci Rep 2017;17:22.  Back to cited text no. 25
    
26.
Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke 2009;40:2977–82.  Back to cited text no. 26
    
27.
Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R. Endothelial progenitor cells: A new key for endothelial dysfunction in migraine. Neurology 2012;79:474–9.  Back to cited text no. 27
    
28.
Sacco S, Pistoia F, Degan D, Carolei A. Conventional vascular risk factors: Their role in the association between migraine and cardiovascular diseases. Cephalalgia Int J Headache 2015;35:146–64.  Back to cited text no. 28
    
29.
Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C. Estrogen, migraine, and vascular risk. Neurol Sci 2018;39:11–20.  Back to cited text no. 29
    
30.
Hamed SA. The vascular risk associations with migraine: Relation to migraine susceptibility and progression. Atherosclerosis 2009;205:15–22.  Back to cited text no. 30
    
31.
Ligong Z, Jinjin Q, Chunfu C, Congcong L, Xiaojun D. Effect of obesity and leptin level on migraineurs. Med Sci Monit 2015;21:3270–4.  Back to cited text no. 31
    
32.
Stam AH, Weller CM, Janssens ACJ, Aulchenko YS, Oostra BA, Frants RR, et al. Migraine is not associated with enhanced atherosclerosis. Cephalalgia Int J Headache 2013;33:228–35.  Back to cited text no. 32
    
33.
Poyrazoglu HG, Vurdem UE, Arslan A, Uytun S. Evaluation of carotid intima-media thickness in children with migraine: A marker of subclinical atherosclerosis. Neurol Sci 2016;37:1663–9.  Back to cited text no. 33
    
34.
Kahya Eren N, Bülbül NG, Yakar Tülüce S, Nazlı C, Beckmann Y. to be or not to be patent: The relationship between migraine and patent foramen ovale. Headache 2015;55:934–42.  Back to cited text no. 34
    
35.
Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: A quantitative systematic review. Cephalalgia Int J Headache 2008;28:531–40.  Back to cited text no. 35
    
36.
Wolf ME, Szabo K, Griebe M, Förster A, Gass A, Hennerici MG, et al. Clinical and MRI characteristics of acute migrainous infarction. Neurology 2011;76:1911–7.  Back to cited text no. 36
    
37.
Butera G, Biondi-Zoccai GGL, Carminati M, Caputi L, Usai S, Bussone G, et al. Systematic review and meta-analysis of currently available clinical evidence on migraine and patent foramen ovale percutaneous closure: Much ado about nothing? Catheter Cardiovasc Interv 2010;75:494–504.  Back to cited text no. 37
    
38.
Malik R, Freilinger T, Winsvold BS, Anttila V, Vander Heiden J, Traylor M, et al. Shared genetic basis for migraine and ischemic stroke: A genome-wide analysis of common variants. Neurology 2015;84:2132–45.  Back to cited text no. 38
    
39.
Winsvold BS, Bettella F, Witoelar A, Anttila V, Gormley P, Kurth T, et al. Shared genetic risk between migraine and coronary artery disease: A genome-wide analysis of common variants. PloS One 2017;12:e0185663.  Back to cited text no. 39
    
40.
Liu F, Benashski SE, Xu Y, Siegel M, McCullough LD. Effects of chronic and acute oestrogen replacement therapy in aged animals after experimental stroke. J Neuroendocrinol 2012;24:319–30.  Back to cited text no. 40
    
41.
Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501–10.  Back to cited text no. 41
    
42.
Danese E, Montagnana M, Lippi G. Platelets and migraine. Thromb Res 2014;134:17–22.  Back to cited text no. 42
    
43.
Calhoun AH, Batur P. Combined hormonal contraceptives and migraine: An update on the evidence. Cleve Clin J Med 2017;84:631–8.  Back to cited text no. 43
    
44.
Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013;87:93–100.  Back to cited text no. 44
    
45.
Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol 2017;216:489.e1-7.  Back to cited text no. 45
    
46.
Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: A systematic review. Headache 2018;58:5–21.  Back to cited text no. 46
    
47.
US Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2016 | CDC [Internet]. 2020 [cited 2020 Oct 30]. Available from: https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html.  Back to cited text no. 47
    
48.
WHO | Medical eligibility criteria for contraceptive use [Internet]. WHO [cited 2020 Oct 30]. Available from: http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/.  Back to cited text no. 48
    
49.
UK medical eligibility criteria for contraceptive use [Internet]. [cited 2020 Oct 30]. Available from: https://www.independentnurse.co.uk/clinical-article/uk-medical-eligibility-criteria-for-contraceptive-use/144422/.  Back to cited text no. 49
    
50.
Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ 2010;340:c2519. doi: 10.1136/bmj.c2519.  Back to cited text no. 50
    
51.
Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol 2012;11:906–17.  Back to cited text no. 51
    
52.
Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med 2005;118(Suppl 1):36S-44S.  Back to cited text no. 52
    
53.
Wammes-van der Heijden EA, Rahimtoola H, Leufkens HGM, Tijssen CC, Egberts ACG. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006;67:1128–34.  Back to cited text no. 53
    
54.
Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U, et al. Vascular safety of erenumab for migraine prevention. Neurology 2020;94:e497–510.  Back to cited text no. 54
    
55.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int J Headache 2018;38:1–211.  Back to cited text no. 55
    
56.
Laurell K, Artto V, Bendtsen L, Hagen K, Kallela M, Meyer EL, et al. Migrainous infarction: A Nordic multicenter study. Eur J Neurol 2011;18:1220–6.  Back to cited text no. 56
    
57.
Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: A systematic review and meta-analysis. Neurology 2013;81:1260–8.  Back to cited text no. 57
    
58.
Rist PM, Dufouil C, Glymour MM, Tzourio C, Kurth T. Migraine and cognitive decline in the population-based EVA study. Cephalalgia Int J Headache 2011;31:1291–300.  Back to cited text no. 58
    
59.
Morton RE, St John PD, Tyas SL. Migraine and the risk of all-cause dementia, Alzheimer's disease, and vascular dementia: A prospective cohort study in community-dwelling older adults. Int J Geriatr Psychiatry 2019;34:1667–76.  Back to cited text no. 59
    
60.
Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, et al. Migraine and risk of cardiovascular disease in women: Prospective cohort study. BMJ 2016;353:i2610. doi: 10.1136/bmj.i2610.  Back to cited text no. 60
    
61.
Adelborg K, Szépligeti SK, Holland-Bill L, Ehrenstein V, Horváth-Puhó E, Henderson VW, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 2018;360:k96.  Back to cited text no. 61
    
62.
Peng K-P, Chen Y-T, Fuh J-L, Tang C-H, Wang S-J. Association between migraine and risk of venous thromboembolism: A nationwide cohort study. Headache 2016;56:1290–9.  Back to cited text no. 62
    
63.
Ripa P, Ornello R, Pistoia F, Carolei A, Sacco S. The renin-angiotensin system: A possible contributor to migraine pathogenesis and prophylaxis. Expert Rev Neurother 2014;14:1043–55.  Back to cited text no. 63
    



 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow